Cannabis
Commented by Stefan Feulner on September 13th, 2023 | 09:55 CEST
Cannabis stocks on a high - Aurora Cannabis, Viva Gold, Canopy Growth
The exorbitant price jumps in the cannabis sector are reminiscent of the golden bull market days between 2015 and 2018. Back then, companies like Canopy Growth saw staggering increases of 5800%, and Aurora Cannabis soared over 6000%. After a years-long dry spell, various companies recently sent strong signs of life with a doubling of the share price within a few days. Additionally, the upward momentum promises to be sustainable as Aurora & Co. slowly move towards profitability.
Read
Commented by André Will-Laudien on September 11th, 2023 | 07:30 CEST
The next steps towards cannabis THC legalization are underway! Canopy, Tilray and BioNTech are taking the lead, and Cantourage Group is experiencing dynamic growth
Cannabis has been decriminalized in some countries but legalized in only a few states. In the US, cannabis is fully legalized in states such as California but outright banned in others such as Texas. While medical use is slowly catching on, the use as an intoxicant and cultivation for personal use remains controversial. Stronger momentum could be sparked by the US Department of Health and Human Services (HHS). The authorities are open to a downgrading of the degree of danger in the categorization of the US Drug Enforcement Administration (DEA). We are talking about two steps from Schedule I to Schedule III, which no longer puts THC on a par with common drugs such as heroin, ecstasy or LSD but classifies them as substances with comparatively little psychological dependence. That would be a revolutionary step. Which stocks can benefit?
Read
Commented by Stefan Feulner on September 6th, 2023 | 07:30 CEST
Cannabis stocks showing signs of life - Aurora Cannabis, Cantourage Group, Canopy Growth
In recent years, the once-hyped cannabis industry was considered a true capital destroyer. Even market leaders like Aurora Cannabis, Tilray, or Canopy Growth saw their stock values plummet by more than 90% at their peak. A letter from the US Department of Health and Human Services has sparked the first signs of a potential revival, which could eventually lead to a sustainable bottoming out in the long run.
Read
Commented by Fabian Lorenz on August 30th, 2023 | 08:30 CEST
Better than Nel & Co.? Megatrend shares Redcare Pharmacy and Cantourage Group recommended as buy
Hydrogen has electrified investors for years. But pure-plays like Plug Power and Nel & Co. are struggling to get their numbers in order and are far from profitable business models. As a result, these shares are not much fun at the moment, and analysts see further downside potential. In such a situation, it is worth taking a look at other megatrend stocks. Redcare Pharmacy (formerly Shop Apotheke) is benefiting from online pharmacy and e-prescription trends. The share has already more than doubled this year. Investors can profit from the cannabis trend with the German Cantourage Group. The Company is growing strongly and the share price has come to rest (before the storm). Both shares are recommended to buy by analysts.
Read
Commented by Stefan Feulner on July 31st, 2023 | 09:50 CEST
BASF, Cantourage Group, Palantir - Now the analysts speak out
Currently, it is high noon for the release of first-half 2023 earnings. Despite all the uncertainties regarding geopolitical and fiscal policy, the majority of companies surprised positively. As a result, the Dow Jones, DAX, Nasdaq and others were able to climb to new highs for the year. Analysts also see further upside potential for many companies, which could accelerate the rally in the coming weeks.
Read
Commented by André Will-Laudien on July 19th, 2023 | 08:00 CEST
Cannabis 3.0 - will profits be made now? Canopy and Tilray under pressure, Cantourage Group positioned superbly
For a few days now, a long-neglected stock market segment has been attracting attention again: the cannabis industry. The North American industry protagonists Canopy and Tilray have recently attracted some stock market turnover again, but skepticism remains high. For those investors who did not exit in time, they had to write off around 95% of their investment in the last 2 years, and experts suspect that the revaluation of the former high-flyers is not yet complete. We take a look at the nebulous scenery of hemp speculation.
Read
Commented by Fabian Lorenz on February 14th, 2023 | 15:46 CET
Biotech stocks on the verge of a breakout? Evotec, BioNTech, Cardiol Therapeutics
Biotech stocks have largely missed out on the rally of recent weeks. But this could change. Some have interesting chart constellations or a positive news flow. Sooner or later, the stock should then also react with a breakout. After the horror year 2022, Evotec received several positive reports within a few days. The share price has also jumped. At BioNTech, investors are looking away from the COVID-19 vaccine and towards the development pipeline. But, analysts disagree. Are 100% share price gains on the cards? Analysts believe that Cardiol Therapeutics' stock has even more potential than that. Its main product against heart inflammation is already in the Phase II pilot study, and the necessary capital for further development is available. All three shares are recommended as a buy by analysts.
Read
Commented by Armin Schulz on February 8th, 2023 | 11:49 CET
BioNTech, Pfizer, Cardiol Therapeutics, Bayer - Biotech stocks facing a revival?
The BIO Deutschland association represents the German biotech industry. According to an announcement on January 18, financing of biotech companies plummeted by 2/3 in 2022. Overall, the sector raised only EUR 920 million in equity. During the Corona pandemic, many biotech stocks did well. Subsequently, profit-taking occurred and rising interest rates put additional pressure on stocks. That could change in 2023. Meanwhile, some companies are valued low, and so these companies appear on the radar of investors from the United States. According to Handelsblatt, Water Street, an investment company focused on pharma and biotech, has already invested EUR 1 billion, mainly in Germany. A total of EUR 6 billion is to be invested.
Read
Commented by Nico Popp on February 2nd, 2023 | 18:04 CET
Bulging pipeline at BioNTech, Cardiol Therapeutics - what is the problem at Aurora Cannabis?
He who heals is right. It is not quite that simple with active ingredients that are about to be approved. Drugs and vaccines must undergo extensive studies and, last but not least, have to prevail against the existing competition. We look at the pipelines of three hot stocks and venture a forecast: Where is the greatest potential for investors?
Read
Commented by Fabian Lorenz on December 1st, 2022 | 11:55 CET
Comeback stocks: Nel, Aurora Cannabis, Barrick Gold, Tocvan Ventures
Gold, cannabis and hydrogen could be among the top trends of the coming year - also on the stock market. Due to full order books, Nel could be poised for a comeback in 2023. At least sales are already secured until mid-2024. Now, all that is left is to cut the loss to reach analysts' price targets. Aurora Cannabis has largely completed its turnaround and is also hoping for legalization in Europe and the US. Driven by a strong gold price, mining stocks have already jumped. Now exploration companies should follow. Tocvan Ventures is one of them. And with the gold explorer, investors can look forward to a regular news flow in the coming year. Are the three candidates comeback stocks in 2023?
Read